ScoreComparison
Why is AnaptysBio, Inc. ?
1
The company has declared Positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 4.48 MM
- NET SALES(HY) At USD 133.81 MM has Grown at 88.77%
- NET PROFIT(HY) Higher at USD -3.27 MM
2
With ROE of -35.56%, it has a risky valuation with a 44.35 Price to Book Value
- Over the past year, while the stock has generated a return of 278.00%, its profits have risen by 90.9%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 278.00% in the last 1 year, much higher than market (S&P 500) returns of 16.00%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to AnaptysBio, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is AnaptysBio, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
AnaptysBio, Inc.
263.56%
1.75
73.55%
S&P 500
15.76%
1.22
13.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
25.62%
EBIT Growth (5y)
31.99%
EBIT to Interest (avg)
-10.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.26
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
44.35
EV to EBIT
33.76
EV to EBITDA
32.14
EV to Capital Employed
386.87
EV to Sales
6.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1145.84%
ROE (Latest)
-35.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 18.08 MM
NET SALES(9M)
At USD 161.29 MM has Grown at 73.16%
PRE-TAX PROFIT(Q)
At USD 47.75 MM has Grown at 817.33%
DEBTORS TURNOVER RATIO(HY)
Highest at 8.96 times
OPERATING PROFIT MARGIN(Q)
Highest at 243.59 %
NET PROFIT(Q)
Highest at USD 229.24 MM
EPS(Q)
Highest at USD 6.19
-6What is not working for the Company
NET SALES(Q)
At USD 27.49 MM has Fallen at -52.69%
RAW MATERIAL COST(Y)
Grown by 101.04% (YoY
CASH AND EQV(HY)
Lowest at USD 450.6 MM
DEBT-EQUITY RATIO
(HY)
Highest at 996.17 %
Here's what is working for AnaptysBio, Inc.
Pre-Tax Profit
At USD 47.75 MM has Grown at 817.33%
over average net sales of the previous four periods of USD -6.66 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 229.24 MM has Grown at 3,523.18%
over average net sales of the previous four periods of USD -6.7 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 18.08 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit Margin
Highest at 243.59 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Highest at USD 229.24 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 6.19
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 8.96 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for AnaptysBio, Inc.
Net Sales
At USD 27.49 MM has Fallen at -52.69%
over average net sales of the previous four periods of USD 58.1 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 450.6 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 996.17 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 101.04% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
